Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities.

0 Comments | M2 Presswire, July, 2007

M2 PRESSWIRE-11 July 2007-EIExplorationInvestor: Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:11072007 Exploration Investor strives to provide you with outstanding market results.

We will be your number one resource for all your small and large cap needs. While working to keep you in touch with market activity, we also will keep you updated on the latest press. Today, July 11th we have identified, Cell Therapeutics, Inc. (Nasdaq:CTIC) due to the attention they received after this recent corporate developments. Cell Therapeutics, Inc. (Nasdaq:CTIC) announced today that interim results of its phase II/III trial comparing CPOP-R,...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)